- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Page 61
Wish comes true in $1.1bn IPO
The mobile commerce platform developer priced its initial public offering at the top of its range, with JD.com set to exit in the flotation.
Dec 16, 2020Innoviz joins Collective for $1.4bn reverse merger
Phoenix Insurance and Magna International are among the backers of a $200m PIPE investment as the lidar sensor provider prepares to list on Nasdaq.
Dec 16, 2020Blade cuts to reverse merger deal
The Airbus Helicopters-backed air transport service will go public through the deal, with the combined company to be valued at $825m.
Dec 16, 2020AbCellera accomplishes $483m initial public offering
Shares in the antibody discovery platform developer, advancing UBC research, opened at more than three times their IPO price to net it a valuation topping $15bn.
Dec 14, 2020AbCellera accomplishes $483m initial public offering
The Eli Lilly-backed antibody discovery platform developer's shares opened at more than three times their IPO price to net it a valuation topping $15bn.
Dec 14, 2020Analysis: DoorDash goes public in $3.37bn IPO
The company priced an upsized IPO nearly doubling its valuation six months ago. It is part of a the food delivery space which was given a boost by the pandemic.
Dec 14, 2020Medirom seeks healthy returns in US IPO
The CCC Marketing-backed salon operator has set a range for an initial public offering set to net it between $16.8m and $19.2m.
Dec 11, 2020Airbnb aces IPO to raise $3.49bn
The Alphabet-backed accommodation marketplace priced its initial public offering well above its range in the second huge flotation this week, to secure a $47bn valuation.
Dec 10, 2020DoorDash lets in $3.37bn through IPO
SoftBank Vision Fund is the largest investor in the food delivery service, which has priced an upsized initial public offering roughly doubling its valuation six months ago.
Dec 9, 2020Silverback swells IPO to near $278m
The underwriters have taken up the over-allotment option in BMS and Celgene-backed oncology drug developer Silverback's initial public offering.
Dec 9, 2020About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


